0001140361-21-005130.txt : 20210216
0001140361-21-005130.hdr.sgml : 20210216
20210216215727
ACCESSION NUMBER: 0001140361-21-005130
CONFORMED SUBMISSION TYPE: 5
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201231
FILED AS OF DATE: 20210216
DATE AS OF CHANGE: 20210216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GRANADILLO PEDRO P
CENTRAL INDEX KEY: 0001217544
FILING VALUES:
FORM TYPE: 5
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36829
FILM NUMBER: 21642458
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ROCKET PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001281895
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 350 FIFTH AVENUE
STREET 2: SUITE 7530
CITY: NEW YORK
STATE: NY
ZIP: 10118
BUSINESS PHONE: 646-440-9100
MAIL ADDRESS:
STREET 1: 350 FIFTH AVENUE
STREET 2: SUITE 7530
CITY: NEW YORK
STATE: NY
ZIP: 10118
FORMER COMPANY:
FORMER CONFORMED NAME: INOTEK PHARMACEUTICALS CORP
DATE OF NAME CHANGE: 20040226
5
1
form5.xml
FORM 5
X0306
5
2020-12-31
0
0
0001281895
ROCKET PHARMACEUTICALS, INC.
RCKT
0001217544
GRANADILLO PEDRO P
C/O ROCKET PHARMACEUTICALS, INC.
9 CEDARBROOK DRIVE
CRANBURY
NJ
08512
true
Stock Option (Right to Buy)
14.56
2020-12-28
5
G
0
30000
0
D
2029-01-28
Common Stock
30000
0
D
Stock Option (Right to Buy)
14.56
2020-12-28
5
G
0
30000
0
A
2029-01-28
Common Stock
30000
30000
I
By Ann Granadillo Lowe 2020 Revocable Trust dated 12/28/2020
Stock Option (Right to Buy)
18.75
2020-12-28
5
G
0
40000
0
D
2028-03-29
Common Stock
40000
0
D
Stock Option (Right to Buy)
18.75
2020-12-28
5
G
0
40000
0
A
2028-03-29
Common Stock
40000
40000
I
By Ann Granadillo Lowe 2020 Revocable Trust dated 12/28/2020
Stock Option (Right to Buy)
19.9
2020-12-28
5
G
0
20000
0
D
2030-06-16
Common Stock
20000
0
D
Stock Option (Right to Buy)
19.9
2020-12-28
5
G
0
20000
0
A
2030-06-16
Common Stock
20000
20000
I
By Paul Andrew Granadillo 2020 Irrevocable Trust dated 12/28/2020
This option represents a right to purchase a total of 30,000 shares of the Issuer's Common Stock, all of which are currently vested and exercisable.
This option represents a right to purchase a total of 40,000 shares of the Issuer's Common Stock, 37,778 of which are currently vested and exercisable, with the remaining 2,222 shares vesting in equal monthly installments on each of February 28, 2021 and March 29, 2021.
This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 16, 2021.
/s/ Sara Turken, Attorney-in-Fact
2021-02-16